Well Pharmaceutical(SH:603351) Zheng Quan Zhi Xing·2025-07-17 10:21Summary of Key Points Core Viewpoint - The announcement details a share reduction plan by a major shareholder of Nanjing Weier Pharmaceutical Group Co., Ltd., indicating a strategic move to meet funding needs while maintaining control over the company by its major stakeholders [1][2]. Group 1: Major Shareholder Information - Nanjing Shuntai Zonghua Venture Investment Partnership (Limited Partnership) holds 10,142,990 shares, representing approximately 7.49% of the total share capital of the company [1][2]. - The shares were acquired through pre-IPO holdings and capital reserve conversion after the IPO [1][2]. Group 2: Share Reduction Plan Details - The shareholder plans to reduce holdings by up to 1,354,390 shares, which is not more than 1% of the total share capital, through centralized bidding from August 20, 2025, to November 17, 2025 [1][2]. - The reduction does not include shares held indirectly by the company's controlling shareholders and actual controllers [1][2]. Group 3: Shareholder Commitments - Senior management has made commitments regarding share transfer limits, stating that during their tenure, they will not transfer more than 25% of their total shareholdings annually after the lock-up period [4]. - The commitments also include a restriction on transferring shares for six months post-resignation [4]. Group 4: Compliance and Regulatory Framework - The share reduction plan complies with relevant laws and regulations, including the Securities Law and the Shanghai Stock Exchange rules [5]. - The company will monitor the progress of the share reduction and fulfill its information disclosure obligations [5].